Regeneron Pharmaceuticals, Inc. $REGN Position Raised by Sumitomo Mitsui DS Asset Management Company Ltd

by · The Cerbat Gem

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,171 shares of the biopharmaceutical company’s stock after buying an additional 911 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Regeneron Pharmaceuticals were worth $11,504,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Arjuna Capital increased its holdings in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 14 shares during the last quarter. Boyd Watterson Asset Management LLC OH boosted its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after acquiring an additional 15 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in Regeneron Pharmaceuticals by 1.8% in the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after acquiring an additional 15 shares during the last quarter. Aaron Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 1.5% in the first quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 16 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 16 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on REGN shares. UBS Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $660.00 to $978.00 in a research note on Thursday, October 15th. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Raymond James Financial increased their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $845.59.

Read Our Latest Research Report on REGN

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $807.48 on Wednesday. The company’s 50 day moving average is $791.41 and its 200-day moving average is $721.87. Regeneron Pharmaceuticals, Inc. has a 12-month low of $572.75 and a 12-month high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market cap of $83.14 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $12.81 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.98 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).